As long as the price is right there will be quite a few 'Yea' votes in support of the transaction.
I don't think we're there yet for the entire platform for many obvious reasons, not the least of which is more clinical proof needed to unequivocally showcase outcomes across a broad range of indications that meet statistical significance and are based on a larger test population. Until then there will likely be a significant gap between asking and bidding.
Plus - no idea when the in-earnest conversations with pharma started and how deep they are but it's typically a 6-9 month process and often crossing a year to finalize and publicize.
But I agree this is (with or without the Nader staying/going component) as likely long term scenario - in part or in full scope of the platform's reach.
Market Data 
Markets 
AI
